BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Huntington's disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for Huntington disease: 20 (14 sponsors; 1 newly posted in the last 180 days, 1 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 10, rank 69 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 4, Phase 2 8, Phase 3 6, Phase 4 0, N/A 2.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Skyhawk Therapeutics, Inc. | 3 | P3 3 | 0 | 1 |
| Novartis Pharmaceuticals NVS | 2 | P3 1, P2 1 | 0 | 0 |
| Neurocrine Biosciences NBIX | 1 | P3 1 | 0 | 0 |
| Prilenia new entrant | 1 | P3 1 | 1 | 0 |
| Hoffmann-La Roche | 3 | P2 2, P1 1 | 0 | 1 |
| UniQure Biopharma B.V. QURE | 2 | P2 2 | 0 | 0 |
| Alnylam Pharmaceuticals ALNY | 1 | P1 1 | 0 | 0 |
| AskBio France, SAS, a subsidiary of AskBio Inc. | 1 | P2 1 | 0 | 0 |
| BioSensics | 1 | NA 1 | 0 | 0 |
| ExoRNA Bioscience | 1 | P2 1 | 0 | 0 |
| InSightec | 1 | NA 1 | 0 | 0 |
| Luye Pharma Group Ltd. | 1 | P1 1 | 0 | 0 |
| Sarepta Therapeutics, Inc. SRPT | 1 | P1 1 | 0 | 0 |
| Vico Therapeutics B. V. | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Prilenia.
Recently stopped trials
- NCT04400331 Neurocrine Biosciences - terminated: Sponsor Decision Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntingt
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No industry Phase 2/3 readouts in the next 90 days. | ||||||
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-05-01 | PDUFA date (company-disclosed) | pending | uniQure N.V. QURE | ifezuntirgene | PDUFA May 1, 2027 - uniQure N.V. (ifezuntirgene) |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| None found. | ||||||
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Huntington disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.